These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23582949)

  • 1. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
    Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
    Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
    Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
    Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
    Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
    Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
    Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
    Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].
    Salomon L; Ploussard G; Coloby P; Kouri G; Lebret T; Méjean A; Prunet D; Soulié M
    Prog Urol; 2014 May; 24(6):367-73. PubMed ID: 24821560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ; Teh BS; Henary H; Khan M; Saxena S
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.